Structure Therapeutics (GPCR) Change in Accured Expenses (2022 - 2026)

Structure Therapeutics' Change in Accured Expenses history runs 5 years deep, the most recent figure standing at -$134000.0 for Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 86.51% year-over-year to -$134000.0 in Q1 2026; TTM through Mar 2026 was $22.4 million, a 129.28% increase from a year earlier, with the FY2025 full-year figure at $21.5 million, up 178.79% from the prior year.
• Change in Accured Expenses fell to -$134000.0 in Q1 2026 per GPCR's latest filing, from $15.0 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $15.0 million in Q4 2025 and bottomed at -$3.0 million in Q1 2024.
• The 5-year median for Change in Accured Expenses is $2.5 million (2022), against an average of $2.5 million.
• Across the five-year window, Change in Accured Expenses jumped 5526.79% in 2023 and sank 446.67% in 2024, its largest moves.
• Year by year, Change in Accured Expenses stood at $56000.0 in 2022, then soared by 5526.79% to $3.2 million in 2023, then slipped by 4.03% to $3.0 million in 2024, then soared by 396.76% to $15.0 million in 2025, then slumped by 100.89% to -$134000.0 in 2026.
• Per Business Quant, the three latest GPCR Change in Accured Expenses figures stand at -$134000.0 (Q1 2026), $15.0 million (Q4 2025), and $3.9 million (Q3 2025).